Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
INmune Bio (NASDAQ:INMB) & Pulmatrix (NASDAQ:PULM) Head-To-Head Review
01:22am, Friday, 16'th Jan 2026
Pulmatrix (NASDAQ: PULM - Get Free Report) and INmune Bio (NASDAQ: INMB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on th
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently publis
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfu
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
08:00am, Tuesday, 18'th Nov 2025
Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Thursday, 06'th Nov 2025
INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wal
Focus Partners Advisor Solutions LLC Acquires 37,224 Shares of INmune Bio, Inc. $INMB
03:27am, Sunday, 02'nd Nov 2025
Focus Partners Advisor Solutions LLC raised its holdings in shares of INmune Bio, Inc. (NASDAQ: INMB) by 321.2% during the second quarter, according to its most recent filing with the SEC. The firm ow
INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
11:16pm, Thursday, 30'th Oct 2025
INmune Bio, Inc. ( INMB ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Daniel Carlson David Moss - President, CEO, Treasurer, Secretary & Director Mark Lowdell - Chief Scien
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
04:05pm, Thursday, 30'th Oct 2025
BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that har
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
07:00am, Tuesday, 14'th Oct 2025
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will p
INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
05:56pm, Monday, 08'th Sep 2025
INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
03:23pm, Friday, 08'th Aug 2025
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David
INmune Bio (INMB) Q2 Loss Widens 110%
06:45pm, Thursday, 07'th Aug 2025
INmune Bio (INMB) Q2 Loss Widens 110%
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
07:00am, Thursday, 31'st Jul 2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage i
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel s
